1. Six-year monitoring of the donor-specific immune response to cryopreserved aortic allograft valves: Implications with valve dysfunction 
Giulio Pompilio, MD, PhD, GianLuca Polvani, MD, Giuseppe Piccolo, MD, Anna Guarino, BS, Angela Nocco, BS, Annalisa Innocente, Massimo Porqueddu, MD, PhD, Luca Dainese, MD, Fabrizio Veglia, PhD, Andrea Sala, MD, Paolo Biglioli, MD 
The Annals of Thoracic Surgery 
Volume 78, Issue 2, Pages (August 2004)
DOI: /j.athoracsur

2. Fig 1
Percent of recipients with a positive panel-reactive antibody (PRA) during the follow-up period. (Pts = patients.)
The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur )

3. Fig 2
Kinetics of HLA antibody production, measured as panel-reactive antibody (PRA) activity, after cryopreserved allograft valve replacement. (HLA = human leukocyte antigen; Pts = patients.)
The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur )

4. Fig 3
Freedom from structural deterioration (%) for patients with and without a peak panel-reactive antibody (PRA) more than 80%. PeakPRA > 80% (squares); peakPRA < 80% (triangles). (Pts = patients.)
The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur )

5. Fig 4
Freedom from structural deterioration (%) for patients with and without a 6-year permanent panel-reactive antibody (PRA) more than 70%. PermanentPRA < 70% (triangles); permanentPRA > 70% (squares). (Pts = patients.)
The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur )